Loading...
•
Sep 30, 2021
Kodiak Sciences Q3 2021 Earnings Report
Announced financial results for the third quarter ended September 30, 2021.
Key Takeaways
Kodiak Sciences reported a net loss of $67.5 million for the third quarter of 2021, with cash and cash equivalents of $799.2 million. The company is progressing with its KSI-301 clinical program and anticipates topline data readouts beginning in early 2022.
Anticipate DAZZLE study topline data in wet AMD in Q1 2022.
Expect BEACON study topline data in retinal vein occlusion in mid-2022.
GLEAM and GLIMMER DME studies are over two-thirds and three-quarters enrolled, respectively, with completion expected in Q1 2022.
DAYLIGHT wet AMD study enrollment is robust and may read out ahead of GLEAM and GLIMMER.
Forward Guidance
Kodiak Sciences expects to announce topline data for DAZZLE in Q1 2022 and BEACON in mid-2022. They also anticipate completing enrollment in GLEAM and GLIMMER in Q1 2022 and DAYLIGHT in the first half of 2022.
Positive Outlook
- Announce topline data for DAZZLE, pivotal study of KSI-301 in wet AMD (long-interval dosing), 1Q 2022.
- Announce topline data for BEACON, pivotal study of KSI-301 in RVO, mid-2022.
- Complete enrollment in GLEAM and GLIMMER, pivotal studies of KSI-301 in DME (long-interval dosing), 1Q 2022.
- Complete enrollment in DAYLIGHT, pivotal study of KSI-301 in wet AMD (short-interval dosing), 1H 2022
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...